Intersect ENT, Inc. (NASDAQ:XENT) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure |
On February24, 2017, Intersect ENT, Inc. (the Company) issued a
press release announcing that the Company has received approval
from the U.S. Food and Drug Administration (FDA) for its PROPEL
Contour steroid releasing sinus implant. A copy of the Company
press release is furnished and attached as Exhibit 99.1.
The information in this Item 7.01 and Exhibit 99.1 of this
Current Report on Form 8-K are being furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 as amended (Exchange Act), or otherwise subject to
the liabilities of that Section or Sections 11 and 12(a)(2) of
the Securities Act of 1933, as amended (Securities Act). The
information in this Item 7.01 and Exhibit 99.1 shall not be
deemed incorporated by reference in any filing under the
Securities Act, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
ExhibitNo. |
Description |
|
| 99.1 |
Press release entitled Intersect ENT Announces FDA Approval of Newest Steroid Releasing Implant, PROPEL Contour, for Use in Treating the Frontal and Maxillary Sinuses dated February24, 2017. |
About Intersect ENT, Inc. (NASDAQ:XENT)
Intersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant. Intersect ENT, Inc. (NASDAQ:XENT) Recent Trading Information
Intersect ENT, Inc. (NASDAQ:XENT) closed its last trading session up +0.60 at 13.15 with 100,717 shares trading hands.
